---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-033539"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:42:17.482853+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FibroGen enters ATM equity offering agreement for up to $30M with BofA Securities

## Summary
- May sell up to $30M of common stock from time to time through BofA as sales agent.
- BofA will receive a commission of up to 3.0% of gross sales proceeds.
- Company is not obligated to sell any shares; offering may terminate upon sale of all shares or by agreement.
- Shares sold under effective shelf registration (333-280597) and prospectus supplement dated Feb 24, 2025.

## SEC filing metadata
- accession: 0001193125-25-033539
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000119312525033539/0001193125-25-033539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000119312525033539/d921088d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-033539
- JSON: https://secwatch.observer/filing/0001193125-25-033539.json
- Plain text: https://secwatch.observer/filing/0001193125-25-033539.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.